These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
27. Persistent neutropenia in chronic myelogenous leukemia in chronic phase treated with imatinib mesylate. Hwang YY; Tse E; So JC; Wan TS; Kwong YL Am J Hematol; 2009 May; 84(5):302-5. PubMed ID: 19338042 [No Abstract] [Full Text] [Related]
28. The metabolic consequences of imatinib mesylate: Changes on glucose, lypidic and bone metabolism. Breccia M; Alimena G Leuk Res; 2009 Jul; 33(7):871-5. PubMed ID: 19307018 [TBL] [Abstract][Full Text] [Related]
29. Imatinib: novel treatment of immune-mediated kidney injury. Wallace E; Gewin L J Am Soc Nephrol; 2013 Apr; 24(5):694-701. PubMed ID: 23431076 [TBL] [Abstract][Full Text] [Related]
30. Bullous pemphigoid associated with hypereosinophilic syndrome: simultaneous response to imatinib. Hofmann SC; Technau K; Müller AM; Lübbert M; Bruckner-Tuderman L J Am Acad Dermatol; 2007 May; 56(5 Suppl):S68-72. PubMed ID: 17097375 [TBL] [Abstract][Full Text] [Related]
31. The EUTOS prognostic score: review and validation in 1288 patients with CML treated frontline with imatinib. Hoffmann VS; Baccarani M; Lindoerfer D; Castagnetti F; Turkina A; Zaritsky A; Hellmann A; Prejzner W; Steegmann JL; Mayer J; Indrak K; Colita A; Rosti G; Pfirrmann M Leukemia; 2013 Oct; 27(10):2016-22. PubMed ID: 23752173 [TBL] [Abstract][Full Text] [Related]
32. Role of tyrosine kinase inhibition with imatinib in an encapsulating peritoneal sclerosis rat model. Velioglu A; Tugtepe H; Asicioglu E; Yilmaz N; Filinte D; Arikan H; Koc M; Tuglular S; Kaya H; Ozener C Ren Fail; 2013; 35(4):531-7. PubMed ID: 23473055 [TBL] [Abstract][Full Text] [Related]
33. Reversal of vascular leak with imatinib: a role for IL-2? Shin JI; Eisenhut M Am J Respir Crit Care Med; 2014 Jul; 190(1):117-8. PubMed ID: 24983224 [No Abstract] [Full Text] [Related]
34. Long-term remission of lymphocytic hypereosinophilic syndrome with imatinib mesylate. Christoforidou A; Kotsianidis I; Margaritis D; Anastasiadis A; Douvali E; Tsatalas C Am J Hematol; 2012 Jan; 87(1):131-2. PubMed ID: 21919038 [No Abstract] [Full Text] [Related]
35. Reply: Reversal of vascular leak with imatinib: a role for IL-2? van Nieuw Amerongen GP; Aman J; Vonk Noordegraaf A Am J Respir Crit Care Med; 2014 Jul; 190(1):118. PubMed ID: 24983225 [No Abstract] [Full Text] [Related]
36. Successful combination treatment of a patient with progressive juvenile localized scleroderma (morphea) using imatinib, corticosteroids, and methotrexate. Inamo Y; Ochiai T Pediatr Dermatol; 2013; 30(6):e191-3. PubMed ID: 23025697 [TBL] [Abstract][Full Text] [Related]
37. Imatinib-related bone marrow aplasia after complete cytogenetic response in chronic myeloid leukemia. Khan KA; Junaid A; Siddiqui NS; Mukhtar K; Siddiqui S J Coll Physicians Surg Pak; 2008 Mar; 18(3):176-8. PubMed ID: 18460249 [TBL] [Abstract][Full Text] [Related]
38. Overview of second-generation tyrosine kinase inhibitors for patients with imatinib-resistant chronic myelogenous leukemia. Ault P Clin J Oncol Nurs; 2007 Feb; 11(1):125-9. PubMed ID: 17441403 [TBL] [Abstract][Full Text] [Related]
39. Nonadherence to imatinib treatment in patients with gastrointestinal stromal tumors: the ADAGIO study. Mazzeo F; Duck L; Joosens E; Dirix L; Focan C; Forget F; De Geest S; Muermans K; VAN Lierde MA; Macdonald K; Abraham I; De Grève J Anticancer Res; 2011 Apr; 31(4):1407-9. PubMed ID: 21508393 [TBL] [Abstract][Full Text] [Related]